Phase III Depression ResultsThe company did not hold a question-and-answer session because of the planned VOYAGE data release. Karlin said the company believes this represents the largest treatment effect reported in a Phase III major depressive disorder trial. Beyond DT120, Definium said it continues to advance DT402 for autism spectrum disorder. About Definium Therapeutics (NASDAQ:DFTX)Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.